Eplerenone in patients with systolic heart failure and mild symptoms: Analysis of repeat hospitalizations

Circulation

Volumn 126, Issue 19, 2012, Pages 2317-2323

  Rogers, Jennifer K ^a   McMurray, John J V ^b   Pocock, Stuart J ^a   Zannad, Faiez ^c   Krum, Henry ^d   Van Veldhuisen, Dirk J ^e   Swedberg, Karl ^f   Shi, Harry ^g   Vincent, John ^g   Pitt, Bertram ^h  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITÉ DE LORRAINE   (France)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g PFIZER INC   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

clinical trial; eplerenone; heart failure; hospitalization; recurrent events

Indexed keywords

EPLERENONE; PLACEBO;

AGED; ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYMPTOMATOLOGY; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REGRESSION ANALYSIS; RISK FACTORS; SPIRONOLACTONE; TIME FACTORS;

EID: 84868597662     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.110536     Document Type: Article

References (20)

1. Richard Hobbs FD. Clinical burden and health service challenges of chronic heart failure. Br J Gen Pract. 2010;60:611-615.
2. Ekman I, Cleland JG, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. Eur J Heart Fail. 2005;7:699-703. (Pubitemid 41125882)
3. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, Steingart RM. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation. 1993;88:492-501. (Pubitemid 23228048)
4. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail. 2005;11:567-575. (Pubitemid 41463726)
5. Skali H, Pfeffer MA, Lubsen J, Solomon SD. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006;114:2298-2303. (Pubitemid 44801489)
6. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J. 2001;22:1021-1031.
7. Goldenberg I, Hall WJ, Beck CA, Moss AJ, Barsheshet A, McNitt S, Polonsky S, Brown MW, Zareba W. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;58:729-737.
8. Conard MW, Heidenreich P, Rumsfeld JS, Weintraub WS, Spertus J. Cardiovascular Outcomes Research Consortium. Patient-reported economic burden and the health status of heart failure patients. J Card Fail. 2006;12:369-374. (Pubitemid 43817588)
9. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-371. (Pubitemid 35190362)
10. Glynn RJ, Buring JE. Ways of measuring rates of recurrent events. BMJ. 1996;312:364-367. (Pubitemid 26049407)
11. Greenwood M, Yule GU. An inquiry into the nature of frequency distributions representative of multiple happenings with particular reference to the occurrence of multiple attacks of disease or of repeated accidents. J Roy Stat Soc. 1920;83:255-279.
12. Jahn-Eimermacher A. Comparison of the Andersen-Gill model with poisson and negative binomial regression on recurrent event data. Comput Stat Data An. 2008;52:4989-4997.
13. Cleland JGF, Louis AA, Rigby AS, Janssens U, Balk AHMM. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol. 2005;45: 1654-1664. (Pubitemid 40704502)
14. Jaarsma T, van der Wal MHL, Lesman-Leegte I, Luttik M, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJA, Dunselman PHJM, Tijssen JGP, Hillege HL, van Veldhuisen DJ. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart failure (COACH). Arch Intern Med. 2008;168:316-324. (Pubitemid 351281679)
15. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics. 2000;56:554-562. (Pubitemid 30422648)
16. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalisation And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12:617-622.
17. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
18. Hsu L, Gorfine M, Malone K. On robustness of marginal regression coefficient estimates and hazard functions in multivariate survival analysis of family data when the frailty distribution is mis-specified. Stat Med. 2007;26:4657-4678. (Pubitemid 350020398)
19. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-1487. (Pubitemid 47480639)
20. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009;119:969-977.